演題詳細

一般口演 / Oral Session

【E】一般口演 16 (Oral Session 16) :MDS:Clinical Research 3

print

日程
2013年10月11日(金)
時間
10:00 - 11:30
会場
第14会場 / Room No.14 (札幌市教育文化会館 3F 研修室305)
座長・司会
石川 隆之 (Takayuki Ishikawa):1
1:Department of Hematology, Kobe City Medical Center General Hospital, Japan
 
前へ戻る

A nationwide survey of hypoplastic myelodysplastic syndrome (A multicenter retrospective study)

演題番号 : OS-1-81

小林 隆 (Takashi Kobayashi):1、南谷 泰仁 (Yasuhito Nannya):1、市川 幹 (Motoshi Ichikawa):1、小原 尚恵 (Takae Kohara):2、小船 雅義 (Masayoshi Kobune):3、原田 浩徳 (Hironori Harada):4、米村 雄士 (Yuji Yonemura):5、松田 晃 (Akira Matsuda):6、川端 浩 (Hiroshi Kawabata):7、通山 薫 (Kaoru Tohyama):8、宮崎 泰司 (Yasushi Miyazaki):9、黒川 峰夫 (Mineo Kurokawa):1

1:Dept. Hematology and Oncology, the University of Tokyo, Tokyo, Japan、2:Department of Hematology and Oncology, Osaka University, Osaka, Japan、3:Dept. Medical Oncology and Hematology, Sapporo Medical University, Sapporo, Japan、4:Res. Inst. Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan、5:Dept. Transfusion Medicine and Cell Therapy, Kumamoto University, Kumamoto, Japan、6:Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan、7:Dept. Hematology and Oncology, Kyoto University, Kyoto, Japan、8:Dept. Laboratory Medicine (Laboratory Hematology), Kawasaki Medical School, Kurashiki, Japan、9:Dept. Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan

 

Adequate treatments for hypoplastic myelodysplastic syndrome (hMDS) are still unknown despite its risk for death of bone marrow (BM) failure. To elucidate hMDS' characteristics and evaluate its therapeutics, we launched a nationwide survey. In this interim analysis, we have collected data from 11 institutions and the central review team of the National Research Group on Idiopathic Bone Marrow Failure Syndromes, and compared the characteristics and treatments between hMDS and non-hMDS patients. Patients with hMDS (MDS with BM cellularities less than 30% (20% for 60 years and above)) diagnosed in April 2003 - March 2012 were enrolled. The percentage of hMDS patients was 7.2% (98 out of 1368). hMDS patients were 66.3% male, 32.7% with histories of malignancies or hematological disorders, 59.2% with low/intermediate-1 risks, 50.0% with RCUD/RCMD, 9.2% with MDS-U in WHO. BM biopsies were performed for 43.9% of hMDS patients, and the concordance of cellularities (<10% of difference) was 50.0%. Treatments for hMDS consisted of transplantation (15.3%), observation (25.5%), best supportive care (16.3%), vitamin K/D (24.5%), immunosuppressive therapies (19.0%), anabolic steroid (15.3%), and azacitidine (7.1%) (the percentage includes second-line therapies and thereafter). Although overall survivals were not statistically different between hMDS and non-hMDS (P=0.38), less patients progressed to leukemia (5.8% vs 23.1%, P<0.01) and more hMDS patients tended to die of BM failure (11.5% vs 3.8%, P=0.14). This study is still ongoing, expecting to establish data of >200 hMDS cases.

前へ戻る